Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Epilepsy and seizure classification

Medial pulvinar stimulation for focal drug-resistant epilepsy: interim 12-month results of the PULSE study.

Francesca Pizzo; Romain Carron; Virginie Laguitton; Audrey Clement; Bernard Giusiano; Fabrice Bartolomei

Originally published in Frontiers in neurology · 2024-12-10

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Objective This study aims to evaluate the efficacy and safety of deep brain stimulation (DBS) of the medial pulvinar nucleus (PuM) in reducing seizure frequency and addressing comorbidities in patients with drug and vagal nerve-resistant focal epilepsy. Methods This is an open-label prospective treatment trial with a planned enrollment of 12 patients suffering from medically refractory epilepsy (Clinical trial gov NCT04692701), for which the interim 12-month post-implantation results for the first 6 patients are being reported. Inclusion criteria were focal epilepsy not suitable for or after failed surgical intervention and previous failure of neurostimulation therapies (vagus nerve stimulation or anterior thalamic nucleus DBS). Evaluations included seizure diaries, neuropsychological assessments, and scales for depression, anxiety, quality of life, and seizure severity. PuM DBS was performed using ROSA robotic assistance, with follow-ups every 3 months for 1 year. Results Out of six patients, five completed 1-year follow-up (one patient died prematurely).

Discussion

We reported preliminary results on six patients in an open clinical trial testing median pulvinar DBS in focal epilepsy. The final study includes 12 patients with a 2-year FU. Patients selected for the procedure are very complex cases of non-surgical drug-resistant epilepsy that failed to respond to VNS, and half of them also failed ANT-DBS.

Conclusion

In conclusion, we felt it was essential to publish the preliminary results of this study, given the current enthusiasm for PuM and its stimulation in epilepsy (22, 36, 38, 46). We observed a trend toward a positive effect on seizure severity, quality of life, and cognition. While the impact on seizures is more variable, two patients responded well. The full report on the 12-patient study after a 2-year follow-up will allow us to confirm these trends in the future.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?